FIG. 1



15
10
5
0
ppm / 20min
2h. 20min
ORAL
GAVAGE
HMB
250mg/Kg
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
FRACTION

FIG. 2



5
4
3
2
1
0
ppm / 20min
2h. 20min
ORAL
GAVAGE
HMB
250mg/Kg
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
FRACTION

FIG. 3A




FIG. 3B




FIG. 3C




FIG. 4




FIG. 5A



MEF2
a
300
250
200
150
100
50
0
Transcriptional activity
Relative luciferase units (%)
CONTROL
HMB 25 µM

FIG. 5B



ERK1/2 inhibitor (PD98059)
150
100
50
0
MEF2 Transcriptional activity
Relative luciferase units (%)
CONTROL
HMB 25 µM

FIG. 5C



Akt inhibitor (LY294002)
MEF2 Transcriptional activity
Relative luciferase units (%)
150
100
50
0
CONTROL
HMB 25 µM

FIG. 5D



mTOR inhibitor (rapamycin)
MEF2 Transcriptional activity
Relative luciferase units (%)
250
200
150
100
50
0
a
CONTROL
HMB 25 µM

FIG. 6



Cell Proliferation/Viability (%)
200
150
100
50
0
a
CONTROL
HMB 25 µM

FIG. 7

